X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (532) 532
gastroenterology & hepatology (356) 356
index medicus (341) 341
female (331) 331
male (328) 328
adult (325) 325
hepatitis b (305) 305
hepatitis b, chronic - drug therapy (277) 277
hbeag (267) 267
hbeag seroconversion (243) 243
middle aged (233) 233
antiviral agents - therapeutic use (230) 230
hepatitis b e antigens - blood (228) 228
hepatitis b virus (228) 228
hepatitis b virus - genetics (224) 224
chronic hepatitis b (213) 213
lamivudine (206) 206
hepatocellular-carcinoma (203) 203
seroconversion (172) 172
hepatitis b, chronic - virology (165) 165
hepatitis (159) 159
treatment outcome (159) 159
virology (158) 158
dna, viral - blood (156) 156
interferon (147) 147
hepatitis b, chronic - immunology (139) 139
genotype (133) 133
therapy (127) 127
infection (126) 126
adolescent (124) 124
hepatitis b virus - immunology (122) 122
hepatitis b surface antigens - blood (117) 117
e-antigen seroconversion (116) 116
natural-history (115) 115
infectious diseases (112) 112
antigens (108) 108
viral load (106) 106
virus diseases (106) 106
digestive system diseases (105) 105
virus-infection (105) 105
aged (103) 103
alanine transaminase - blood (100) 100
hepatitis b e antigen (100) 100
young adult (100) 100
peginterferon alpha-2a (91) 91
adefovir dipivoxil (90) 90
entecavir (90) 90
dna (89) 89
hepatitis b, chronic - blood (89) 89
lamivudine - therapeutic use (88) 88
interferon-alpha - therapeutic use (86) 86
surface-antigen (86) 86
health aspects (85) 85
mutation (85) 85
hepatitis b virus - drug effects (82) 82
e-antigen (80) 80
hepatitis b surface antigen (76) 76
term-follow-up (74) 74
cirrhosis (73) 73
deoxyribonucleic acid--dna (72) 72
hepatitis b e antigens - immunology (71) 71
hbsag (69) 69
child (68) 68
analysis (67) 67
care and treatment (67) 67
hepatocellular carcinoma (67) 67
risk factors (66) 66
antiviral therapy (65) 65
hepatitis b virus - isolation & purification (64) 64
hepatitis b, chronic - diagnosis (63) 63
hepatology (63) 63
research (63) 63
time factors (63) 63
follow-up studies (61) 61
liver (60) 60
prognosis (60) 60
antiviral agents - administration & dosage (59) 59
biomarkers - blood (59) 59
liver cirrhosis (59) 59
guanine - analogs & derivatives (58) 58
hbv (58) 58
hbv dna (58) 58
retrospective studies (57) 57
drug therapy (56) 56
lamivudine therapy (56) 56
virological response (56) 56
drug therapy, combination (55) 55
management (55) 55
pharmacology & pharmacy (55) 55
adenine - analogs & derivatives (54) 54
infections (54) 54
virus infection (54) 54
tenofovir (53) 53
liver cancer (51) 51
risk (51) 51
genetic aspects (48) 48
tenofovir disoproxil fumarate (48) 48
disease progression (47) 47
hbeag-negative patients (47) 47
medicine & public health (47) 47
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (714) 714
Korean (18) 18
Japanese (7) 7
Spanish (4) 4
Chinese (3) 3
French (3) 3
Czech (1) 1
Polish (1) 1
Russian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal of Viral Hepatitis, ISSN 1352-0504, 07/2019, Volume 26, Issue 7, pp. 828 - 834
Hepatitis B e antigen ( HB eAg) seroconversion experienced during nucleo(s)tide analogue ( NUC ) therapy is often not sustained. We aimed to study whether... 
entecavir | hepatitis B core‐related antigen | HBeAg seroconversion | nucleo(s)tide analogues | tenofovir | hepatitis B core-related antigen | HBCRAG | INFECTIOUS DISEASES | VIROLOGY | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Journal of Viral Hepatitis, ISSN 1352-0504, 01/2019, Volume 26, Issue 1, pp. 126 - 135
Nucleos(t)ide analogues ( NA ) are effective in suppressing hepatitis B virus ( HBV ) replication, but most patients require long‐term treatment. This study... 
clinical trial | hepatitis cure | nucleotide analogue | hepatitis B surface antigen | hepatitis B e antigen | ALPHA-2A | INFECTIOUS DISEASES | GUIDELINES | FOLLOW-UP | RISK | LAMIVUDINE THERAPY | DURABILITY | TENOFOVIR DISOPROXIL FUMARATE | VIROLOGY | INFECTION | HBEAG-POSITIVE PATIENTS | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Journal of Viral Hepatitis, ISSN 1352-0504, 10/2018, Volume 25, Issue 10, pp. 1172 - 1179
Journal Article
Journal Article
Journal Article